MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Perrigo Co PLC

Slēgts

SektorsVeselības aprūpe

24.88 0.48

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

24.5

Max

25.08

Galvenie mērījumi

By Trading Economics

Ienākumi

-24M

-45M

Pārdošana

51M

1.1B

P/E

Sektora vidējais

2,570

57.333

EPS

0.93

Dividenžu ienesīgums

4.76

Peļņas marža

-3.909

Darbinieki

8,379

EBITDA

35M

114M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+39.45% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

4.76%

2.63%

Nākamie ieņēmumi

2025. g. 7. maijs

Nākamais dividenžu datums

2025. g. 17. jūn.

Nākamais Ex dividenžu datums

2025. g. 29. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

85M

3.5B

Iepriekšējā atvēršanas cena

24.4

Iepriekšējā slēgšanas cena

24.88

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Perrigo Co PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. febr. 17:42 UTC

Galvenie tirgus virzītāji

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

2025. g. 27. febr. 23:52 UTC

Peļņas

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

Salīdzinājums

Cenas izmaiņa

Perrigo Co PLC Prognoze

Cenas mērķis

By TipRanks

39.45% augšup

Prognoze 12 mēnešiem

Vidējais 34.5 USD  39.45%

Augstākais 42 USD

Zemākais 27 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Perrigo Co PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

24.09 / 24.825Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.